about
Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsCost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real worldTiming of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy.New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy)Knowledge transfer: what drug information would specialist doctors need to support their clinical practice? Results of a survey and of three focus groups in Italy.HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy.Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy.First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study.The problem of renal function monitoring in patients treated with the novel antiretroviral drugs.Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study.Isolated acute dysphagia due to varicella-zoster virus.Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?Mother-To-Child Transmission of KPC Carbapenemase-Producing Klebsiella Pneumoniae at Birth.Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.Gender differences in HIV infection: is there a problem? Analysis from the SCOLTA cohorts.Decreasing cardiovascular risk in HIV infection between 2005 and 2011.Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase.Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study.Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study.Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.Predictors of protease inhibitor-associated adverse events.The cost of HIV disease in Northern Italy: the payer's perspective.Low frequency of skin reactions in a cohort of patients on raltegravir.Risk factors for lipodystrophy in the CISAI cohort.Cardiovascular risk assessment in antiretroviral-naïve HIV patients.Safety of statin therapy in HIV/hepatitis C virus-coinfected patients.Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study.Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study.
P50
Q30617407-253F2EFD-DB90-4DBF-B1DA-85BC67011E2FQ31020119-E830D83B-EC66-4527-B428-4835CD3DCD39Q33817410-7F35754A-D59C-469B-94BF-B7962B989480Q33878754-314BF47D-4E6C-484E-B0BC-65FF7A5E096EQ34608823-ACBC7C51-3AAA-4DF8-B941-418807C54EC5Q35108221-1B2AD69E-F3D3-4A63-BE68-5D1C24814DC8Q35560802-0B9C011F-5D23-4933-91CC-1DAAA0595A33Q35741765-5D449642-F75E-4ABF-9E46-6C54F4E15B0EQ36119076-74F2565C-7688-4BA9-83C8-70C5189D48CBQ36234850-665BDA61-0BC6-4E15-A59C-0391F0751A8CQ36251587-4DD82CC4-789C-4965-A587-9B5810888F31Q36848229-CEA59873-3AF7-4C34-AB7C-3CD4C9113997Q38779256-A58CB9DD-E029-47B3-81BF-11620028355BQ39203030-A42D597D-72A8-41E3-BBFD-94CBF52D8DB4Q39861096-A7D23D6B-84A5-490C-BB10-45C180D050F2Q40217816-F8C021A0-092F-46C8-8499-B0374BE67D9FQ40375080-F28BA840-61C1-4A1F-90E2-BA36A3587D62Q40439011-12CCA442-6497-48B0-AA38-1FF8F43319F8Q40451390-7A985F6A-8BE7-4302-9920-B1054B24D69AQ41496212-0C5371E2-0A25-4562-9B5D-38A0A12427C1Q41616666-8F92DE75-CD32-40C6-9A37-EDA1E6F17B4EQ42224824-5D66A727-768D-4E6B-AB79-269B52CC7EA2Q42234707-3ED70C11-0C58-4492-817E-DB61CCDDC3FBQ42247735-ADCB81BC-F9A5-4DFD-BFA5-61F487F11352Q42273711-B410731B-84D3-4CFB-8811-88FBCB468330Q42273839-17322E57-A428-491D-B89B-DF3F0BD0EC99Q42729800-5502BA80-A77D-4C9A-B0DC-BE87E318C9B9Q43105609-BAD57E1F-F212-4E3B-A20B-3B6E1EF055AEQ43159176-8313910A-E2BE-48EB-8A43-2FD21428FD99Q43290741-55668335-16B2-4C52-82CB-5B1414A17A50Q43557211-43F0B01C-9255-4DD7-AD4E-117DC49F572EQ43691272-1D229F0C-B86F-437A-A55C-55C868B817B4Q43911880-7F5D9D01-6B9E-4CDA-8B08-F0874BB0F5AAQ44532546-69228340-9863-4FAE-A7E2-0041E898AF71Q44677707-3AD9A3CE-D0A6-48A6-9F2B-5E879538F8EFQ44681586-FF239AF4-E70F-4A4F-9728-439347CE7951Q45230663-C3DD4901-9510-484F-861F-6173753DD049Q45369642-2EAE6C76-FFF1-41B2-B150-D847116B1C2FQ46425864-5F2F6CBE-5313-45A2-8D95-B4783CD58D89Q46627265-EA5AEED3-4DD2-45D7-B3E4-2F5A17898C0C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
P Bonfanti
@nl
P Bonfanti
@sl
Paolo Bonfanti
@en
Paolo Bonfanti
@es
type
label
P Bonfanti
@nl
P Bonfanti
@sl
Paolo Bonfanti
@en
Paolo Bonfanti
@es
altLabel
P Bonfanti
@en
prefLabel
P Bonfanti
@nl
P Bonfanti
@sl
Paolo Bonfanti
@en
Paolo Bonfanti
@es
P106
P1153
55540061000
P21
P31
P496
0000-0001-7289-8823